ImmuPharma PLC (AIM:IMM) has appointed Ketan Patel to its board as an independent non-executive director, bringing decades of investment experience in healthcare and life sciences.
Patel, who joins with immediate effect, began his career at JP Morgan before moving to Insight Investment as a global pharmaceuticals and healthcare analyst.
He later spent more than 20 years at EdenTree Investment Management, where he managed UK equity and global income strategies, consistently delivering top-quartile performance.
A Chartered Financial Analyst, Patel holds postgraduate degrees from the London School of Economics and King’s College London, as well as a BA from Queen Mary University of London.
Tim McCarthy, ImmuPharma’s chief executive, said: “We are extremely pleased to welcome Ketan to our board.
"His expertise in the global pharmaceutical and life science sectors and strong investment acumen will be invaluable as we focus on future strategic partnerships and commercial deals, particularly around our lead autoimmune technology, P140.”
Patel said he was “delighted to be joining the ImmuPharma team at this pivotal stage” and looked forward to contributing to its future success.
ImmuPharma is a London-listed biotechnology company focused on developing innovative treatments for autoimmune and metabolic diseases.